An elevation of serum angiotensin-converting enzyme (ACE) has been reported in some disorders associated with immune activation, e.g. sarcoidosis, HIV infection or ulcerative colitis. Both endothelial cells and macrophages are thought to be the possible source of increased ACE levels. We have investigated serum ACE and neopterin, an indicator of macrophage activation, in 23 patients with solid tumors as well as in 8 controls. Similar ACE levels have been observed in the cancer patients and the controls (2.6 ± 2.1 vs 3.4 ± 1.1 ~at/1, while neopterin has been significantly higher in the cancer patients (15.4 ± 12.6 vs 7.2 ± 2.2 nmol/I, P<O.02). No correlation has been observed between serum ACE and neopterin. We conclude that an elevation of ACE is not present in cancer patients. Macrophage activation in cancer is not accompanied by increased ACE release.
Introduction
Angiotensin-converting enzyme (ACE) is produced mainly by endothelial cells and plays a key role in regulating the metabolism of vasoactive peptides, i.e. the conversion of angiotensin I to angiotensin II and inactivation of bradykinin (1) . ACE production was also demonstrated in macrophages and an increase of serum ACE levels resulting from macrophage activation has been associated with sarcoidosis (2) . More recently, an increase in serum ACE has been also reported in patients with HIV infection and ulcerative colitis (3, 4) , but the cellular source of ACE in these disorders remains to be determined.
Macrophage activation in many clinical situations, including the mentioned disorders, has been associated with a rise in serum and urine neopterin (5, 6, 7, 8) . Increased neopterin production in these conditions is known to result mainly from the action of interferon-gamma, a cytokine released by T-Iym- § Author to whom correspondence should be addressed.
Pteridines / Vol. 5 / No. 4 phocytes (9), on macrophages, and is now widely used to assess immune activation (5) . Elevated urine and serum neopterin levels have been described in many different tumors (5, 10, 11, 12) , reflecting the macrophage activation induced by interferon-gamma.
The aim of the present study was to determine whether the rise in serum neopterin in cancer patients is accompanied by increased serum ACE levels.
Material and Methods

Patients
Twenty-three previously untreated cancer patients, aged 64 ± 10 (42-77) years, were included in the study. Eight patients presented with colorectal cancer, 5 patients had gastric cancer, 4 patients had breast cancer, 2 patients had thyroid cancer, 2 patients had cancer of the esophagus and one patient each had cancer of the pancreas and gastric leiomyosarcoma. Eight subjects, aged 58 ± 11 years, presenting for elected operation for inguinal hernia served as controls.
In all the studied subjects serum sample was taken before any operative treatment and stored in ali quotes at -50't.
Neopterin determination
Serum neopterin was determined using a RIA kit (generously provided by Henning, Berlin, Germany) as described (13) .
ACE measurement
ACE was measured by a colorimetric method (14) . Fifty fJI of the serum sample was incubated with 100 fJI 20.5 mmol/l hippuryl-glycyl-glycine (Sigma, St. Louis, USA) at 37't. After 30 minutes, 100 fJI 0.33 mol/I sodium tungstate (Lachema, Bmo, Czech Republic) and 100 fJl of 0.33 mol/I sulfuric acid (Lachema) were added. After mixing, 1000 fJI of distilled water was added. The solution was then centrifuged (2000 X g for 10 minutes), and 750 fJI of the supernatant was incubated with 50 fJl of 0.1 mmol/I 2,4, 6-trinitrobenzene sulfonic acid (Sigma) and 1000 fJI of borate buffer, pH = 9.6, (Lachema) at room temperature. After 30 minutes the absorbance was read at 405 nm. A standard curve was constructed using glycyl-glycine (Sigma).
Statistical analysis
The significance of differences was assessed using the Mann-Whitney U test. The correlation was studied by Spearman rank correlation coefficient. The decision on significance was based on p=0.05 significance level. serum neopterin was significantly higher in cancer patients. On the contrary, ACE was not elevated. ACE is an established marker in sarcoidosis (1, 2) . Besides this disease, an increase in ACE was reported in a variety of disorders, including HIV infection (3), ulcerative colitis (4), diabetic angiopathy (15) and chronic fatigue syndrome (16) . An increase in ACE activity could be also produced in experimental inflammation (17) . While in sarcoidosis ACE is thought to be produced by macrophages (1) , the cellular source in other mentioned conditions has not yet been unequivocally identified.
Neopterin is an established index of macrophage activation (5). Our results indicate that macrophage activation in cancer patients is not associated with increased serum ACE levels. ACE appears to be elevated only in a small portion of cancer patients.
In conclusion, serum ACE does not seems to be elevated in cancer patients. Macrophage activation in cancer patients, as reflected by increased serum neopterin, is not accompanied by similar rise in ACE. Increased ACE production by macrophages appears to be peculiar to some conditions, notably sarcoidosis, while an elevation in serum ACE in other disorders might come from endothelial cells, but increased ACE, unlike neopterin, does not seem to be a universal marker of macrophage activation.
